Adherence to the ARB/CCB fixed dose combination tablets and ARB/CCB concomitant therapy, a randomized parallel trial on efficacy and safety

Adherence to the ARB/CCB fixed dose combination tablets and ARB/CCB concomitant therapy, a randomized parallel trial on efficacy and safety - Adherence to the ARB/CCB efficacy and safety study of both fixed dose combination tablets and concomitant usage.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006412

Enrollment

440

Registered

2011-09-27

Start date

2011-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

ARB / CCB combination tablet therapy administered for 2 months CCB and ARB therapy is administered two months with a combination of antihypertensive therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Currently, ARB and CCB in combination with high blood pressure patients (b) Patients with hypertension who are taking a combination tablet weight of each standard internal use (c) Patients over 20 years of age at the time of obtaining informed consent (d) Patients who obtained consent in writing of the study participants

Exclusion criteria

Exclusion criteria: (a) ARB, CCB administration of drugs contraindicated in patients with hypertension and other symptoms (irritability, and pregnant women) (b) Patients deemed unsuitable for the doctor to conduct a study

Design outcomes

Primary

Measure	Time frame
adherence	—

Secondary

Measure	Time frame
blood pressure, pulse rate	—

Countries

Japan

Contacts

Public ContactTakafumi Ishida

Hiroshima University Department of Cardiovascular Medicine

ishidat@hiroshima-u.ac.jp082-257-5540

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026